Aramis Biotechnologies: Company Profile

Background

Aramis Biotechnologies, established in 2023 and headquartered in Quebec City, Canada, specializes in the plant-based production of innovative vaccines. The company leverages over two decades of research to develop a versatile and rapid biomanufacturing platform aimed at addressing current and future public health challenges. As a majority employee-owned entity, Aramis fosters a culture of solidarity and responsibility, with a mission to sustainably meet global human health needs.

Key Strategic Focus

Aramis's strategic objectives include:

Development of Plant-Based Vaccines: Utilizing plant-based biomanufacturing technology to produce innovative vaccines.

Seasonal Influenza Vaccine: Focusing on developing a seasonal flu vaccine with the potential to improve protection for at-risk populations.

Scalable Production Platform: Establishing a next-generation plant-based production system to enhance control, reproducibility, and biomass quality, facilitating rapid response to potential pandemics.

Financials and Funding

In December 2024, Aramis secured $30 million in Series A financing, jointly contributed by employees and private investors. Employees collectively invested $10 million, while a group of Quebec City-area entrepreneurs contributed $20 million. This funding is designated for Phase 1 and 2 clinical trials of the company's seasonal influenza vaccine candidate and to prepare for subsequent Phase 3 studies and commercialization in Canada.

Pipeline Development

Aramis's primary pipeline candidate is a next-generation Virus-Like Particle (VLP) seasonal influenza vaccine. Key development milestones include:

Preclinical Studies: Favorable outcomes compared to current market alternatives.

Phase 1 and 2 Clinical Trials: Scheduled to commence in 2026, focusing on enhancing protection duration and improving immune response, particularly in vulnerable populations such as the elderly.

Technological Platform and Innovation

Aramis's technological innovations encompass:

Proprietary Plant-Based Production System: Utilizing Nicotiana benthamiana plants to produce VLPs, offering a scalable and sustainable alternative to traditional vaccine manufacturing methods.

Next-Generation Closed Plant Production System: Replacing traditional greenhouses with a controlled-environment system to enhance control, reproducibility, and biomass quality, allowing for global scalability.

Streamlined Commercial Scale-Up: Achieving high yields that eliminate the need for scale-up in commercial production, accelerating timelines and reducing costs.

Leadership Team

Aramis's leadership comprises experienced professionals:

Frédéric Ors, Co-founder & CEO: Oversees strategic direction and operations.

Dr. Marc-André D’Aoust, Chief Scientific Officer: Leads scientific research and development initiatives.

The Board of Directors includes:

Pierre Labbé, Chairman: Executive Vice President of Finance at QScale, with over 30 years of financial leadership experience.

Brigitte Barbeau, Director: Former Vice President of International Quality at Sanofi Pasteur, with extensive experience in biopharmaceuticals and vaccine compliance.

Tony D'Amore, Director: Former Vice President of Global Research and Product Development at Sanofi Pasteur, with expertise in bioprocesses and vaccine development.

Serge Ferland, Director: Experienced businessman with a background in the food industry and community involvement.

Paul Marshall, Director: Former leader at Amgen and Baxter, with a focus on optimizing manufacturing processes and technological innovation.

Competitor Profile

Market Insights and Dynamics

The global vaccine market is experiencing significant growth, driven by increasing demand for effective immunization solutions and advancements in biomanufacturing technologies. Plant-based vaccine production is emerging as a promising alternative to traditional methods, offering scalability, sustainability, and rapid response capabilities.

Competitor Analysis

Key competitors in the plant-based vaccine sector include:

Medicago Inc.: A Canadian biopharmaceutical company specializing in plant-based vaccines, known for developing VLP vaccines using Nicotiana benthamiana.

iBio, Inc.: A U.S.-based company utilizing plant-based expression systems for vaccine and therapeutic protein production.

Kentucky BioProcessing, Inc.: Engages in plant-based biomanufacturing, focusing on rapid, scalable vaccine production.

These companies focus on leveraging plant-based platforms to produce vaccines and therapeutics, emphasizing rapid production capabilities and scalability.

Strategic Collaborations and Partnerships

Aramis has established significant partnerships to advance its vaccine development:

Biodextris Inc.: In December 2024, Aramis partnered with Biodextris, a Montreal-based CDMO specializing in complex biologic products, for downstream manufacturing of clinical materials for Phase 1 and 2 trials of its influenza vaccine candidate.

Biologics Manufacturing Centre (BMC): In February 2025, Aramis collaborated with BMC, a non-profit organization dedicated to manufacturing essential biopharmaceutical solutions, for the formulation and finish of its vaccine candidate in preparation for clinical trials.

Operational Insights

Aramis's strategic considerations include:

Leveraging Plant-Based Technology: Utilizing a plant-based platform to produce VLPs, offering a scalable and sustainable alternative to traditional vaccine manufacturing methods.

Rapid Production Capabilities: Achieving high yields that eliminate the need for scale-up in commercial production, accelerating timelines and reducing costs.

Strategic Partnerships: Collaborating with organizations like Biodextris and BMC to enhance manufacturing capabilities and ensure efficient clinical development.

Strategic Opportunities and Future Directions

Aramis's strategic roadmap includes:

Advancing Clinical Trials: Progressing through Phase 1 and 2 clinical trials for its influenza vaccine candidate, with plans for Phase 3 studies and commercialization.